Proteomic analysis of protein expression throughout disease progression in a mouse model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 47, Issue 4, 2015, Pages 915-926

  Fu, Yongyao ^a   Zhao, Deming ^a   Pan, Bo ^b   Wang, Jihong ^a   Cui, Yongyong ^a   Shi, Fushan ^c   Wang, Chunyu ^a   Yin, Xiaoming ^a   Zhou, Xiangmei ^a   Yang, Lifeng ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; DRP 2; HSP 70; Proteomics; UCH L1

Indexed keywords

ACTIN; ACTIN CAPPING PROTEIN; ADENOSINE TRIPHOSPHATASE; ADENYLATE KINASE; ALPHA 1A ADRENERGIC RECEPTOR; AMYLOID PRECURSOR PROTEIN; CHAPERONIN CONTAINING TCP1; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; CREATINE KINASE; CYTOPLASM PROTEIN; HEAT SHOCK PROTEIN 70; MITOCHONDRIAL PROTEIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; PYRUVATE DEHYDROGENASE; SERUM ALBUMIN; UBIQUITIN THIOLESTERASE; APP PROTEIN, HUMAN; PRESENILIN 1; PROTEOME; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DISEASE COURSE; ENERGY METABOLISM; ENZYME ACTIVE SITE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SUBUNIT; PROTEOMICS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; VASCULAR AMYLOIDOSIS; WESTERN BLOTTING; AGING; ANIMAL; DISEASE MODEL; GENETICS; HIPPOCAMPUS; HUMAN; MASS SPECTROMETRY; METABOLISM; PROCEDURES; TRANSGENIC MOUSE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HIPPOCAMPUS; HUMANS; MASS SPECTROMETRY; MICE, TRANSGENIC; PRESENILIN-1; PROTEOME; PROTEOMICS;

EID: 84939443320     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150312     Document Type: Article

References (74)

1. Choi YS, Choe LH, Lee KH (2010) Recent cerebrospinal fluid biomarker studies of Alzheimer's disease. Expert Rev Proteomics 7, 919-929.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 60, 1119-1122.
3. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
4. Iqbal K, Grundke-Iqbal I (2008) Alzheimer neurofibrillary degeneration: Significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12, 38-55.
5. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61, 378-384.
6. Selkoe DJ (2004) Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6, 1054-1061.
7. Glenner GG, Wong CW (1984) Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890.
8. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766.
9. Joachim CL, Morris JH, Selkoe DJ (1989) Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 135, 309-319.
10. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24, 1121-1159.
11. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12, 383-388.
12. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
13. Castellani RJ, SmithMA(2011) Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. J Pathol 224, 147-152.
14. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Siemers E, Sethuraman G, Mohs R (2013)Aphase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 369, 341-350.
15. Salloway S, Sperling R, Brashear HR (2014) Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med 370, 1460.
16. Guerreiro R, Bras J, Hardy J (2013) SnapShot: Genetics of Alzheimer's disease. Cell 155, 968.
17. Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FL, Mitra RD, Faber K, Williamson J, Bird T, Diaz-Arrastia R, Foroud TM, Boeve BF, Graff-Radford NR, St JP, Lawson M, Ehm MG, Mayeux R, Goate AM (2012) Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 7, e31039.
18. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118, 4002-4013.
19. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, Umans L, Schrijvers V, Checler F, Vanderstichele H, Baekelandt V, Dressel R, Cupers P, Huylebroeck D, Zwijsen A, Van Leuven F, De Strooper B (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A 96, 11872-11877.
20. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L (1998) Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: Increased susceptibility of females. Proc Natl Acad Sci U S A 95, 10914-10919.
21. Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA (2003) PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 23, 8989-9003.
22. Jankowsky JL, Slunt HH, Ratovitski T, JenkinsNA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol Eng 17, 157-165.
23. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159-170.
24. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR (2004) APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging 25, 885-892.
25. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, FroschMP(2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24, 516-524.
26. Quinn CC, Gray GE, Hockfield S (1999) A family of proteins implicated in axon guidance and outgrowth. J Neurobiol 41, 158-164.
27. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA (2007) Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11, 153-164.
28. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Zhou XZ, Lu KP, Butterfield DA (2006) Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiol Aging 27, 918-925.
29. Castegna A, AksenovM, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinaserelated protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82, 1524-1532.
30. Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, Butterfield DA (2005) Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: Implications for Alzheimer's disease. Brain Res 1044, 206-215.
31. Tan M, Ma S, Huang Q, Hu K, Song B, Li M (2013) GSK-3alpha/beta-mediated phosphorylation of CRMP-2 regulates activity-dependent dendritic growth. J Neurochem 125, 685-697.
32. Bukau B, Horwich AL (1998) The Hsp70 and Hsp60 chaperone machines. Cell 92, 351-366.
33. Doyle SM, Genest O, Wickner S (2013) Protein rescue from aggregates by powerful molecular chaperone machines. Nat Rev Mol Cell Biol 14, 617-629.
34. Hoshino T, Murao N, Namba T, Takehara M, Adachi H, Katsuno M, Sobue G, Matsushima T, Suzuki T, Mizushima T (2011) Suppression of Alzheimer's disease-related phenotypes by expression of heat shock protein 70 in mice. J Neurosci 31, 5225-5234.
35. Dedmon MM, Christodoulou J, Wilson MR, Dobson CM (2005) Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem 280, 14733-14740.
36. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A 97, 7841-7846.
37. Evans CG, Wisen S, Gestwicki JE (2006) Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem 281, 33182-33191.
38. Magrane J, Smith RC, Walsh K, Querfurth HW (2004) Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci 24, 1700-1706.
39. von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM,Mandelkow E (2001) Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem 276, 48165-48174.
40. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A,Voellmy R, TsuboiY, Dawson TM, Wolozin B, Hardy J, Hutton M (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13, 703-714.
41. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S,Wong E, Mandelkow EM, Cuervo AM, Mandelkow E (2010) Synergy and antagonism of macroautophagy and chaperone-mediated autophagy in a cell model of pathological tau aggregation. Autophagy 6, 182-183.
42. Sabirzhanov B, Stoica BA, Hanscom M, Piao CS, Faden AI (2012) Over-expression of HSP70 attenuates caspasedependent and caspase-independent pathways and inhibits neuronal apoptosis. J Neurochem 123, 542-554.
43. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H (2003) Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A 100, 721-726.
44. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PJ (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209-218.
45. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J (1989) The neuron-specific protein PGP 9. 5 is a ubiquitin carboxyl-terminal hydrolase. Science 246, 670-673.
46. Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, Sato Y, Nishikawa K, Sun YJ, Sakurai M, Harada T, Hara Y, Kimura I, Chiba S, Namikawa K, Kiyama H, Noda M, Aoki S, Wada K (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 12, 1945-1958.
47. Larsen CN, Price JS, Wilkinson KD (1996) Substrate binding and catalysis by ubiquitin C-terminal hydrolases: Identification of two active site residues. Biochemistry 35, 6735-6744.
48. Larsen CN, Krantz BA, Wilkinson KD (1998) Substrate specificity of deubiquitinating enzymes: Ubiquitin C-terminal hydrolases. Biochemistry 37, 3358-3368.
49. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279, 13256-13264.
50. Castegna A, AksenovM, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinaserelated protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82, 1524-1532.
51. Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB, Martins RN (2006) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: An initial assessment. J Alzheimers Dis 10, 391-397.
52. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, Moolman D, Zhang H, Shelanski M, Arancio O (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126, 775-788.
53. Qing H, Zhou W, Christensen MA, Sun X, Tong Y, Song W(2004) Degradation of BACE by the ubiquitin-proteasome pathway. FASEB J 18, 1571-1573.
54. Zhang M, Deng Y, Luo Y, Zhang S, Zou H, Cai F, Wada K, Song W (2012) Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1. J Neurochem 120, 1129-1138.
55. Guglielmotto M, Monteleone D, Boido M, Piras A, Giliberto L, Borghi R, Vercelli A, Fornaro M, Tabaton M, Tamagno E (2012) Abeta1-42-mediated down-regulation of Uch-L1 is dependent on NF-kappaB activation and impaired BACE1 lysosomal degradation. Aging Cell 11, 834-844.
56. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53(Suppl 3), S26-S36, S36-S38.
57. Giasson BI, Ischiropoulos H, LeeVM,Trojanowski JQ (2002) The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 32, 1264-1275.
58. Spillantini MG, Goedert M (1998) Tau protein pathology in neurodegenerative diseases. Trends Neurosci 21, 428-433.
59. Zhao ZB,Wu L, Xiong R,Wang LL, Zhang B,Wang C, Li H, Liang L, Chen SD (2014) MicroRNA-922 promotes tau phosphorylation by downregulating ubiquitin carboxy-terminal hydrolase L1 (UCHL1) expression in the pathogenesis of Alzheimer's disease. Neuroscience 275, 232-237.
60. Hoshi T, Heinemann S (2001) Regulation of cell function by methionine oxidation and reduction. J Physiol 531, 1-11.
61. Fu Y, Zhao D, Yang L (2014) Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease. J Mol Neurosci 54, 739-747.
62. Smith RC, Rosen KM, Pola R, Magrane J (2005) Stress proteins in Alzheimer's disease. Int J Hyperthermia 21, 421-431.
63. Hampel H, ShenY(2009) Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. Scand J Clin Lab Invest 69, 8-12.
64. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J, Crowther DC, Lomas DA, Janciauskiene SM (2007) Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69, 1569-1579.
65. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 118, 140-146.
66. Riemenschneider M, Blennow K, Wagenpfeil S, Andreasen N, Prince JA,LawsSM,Forstl H,KurzA(2006) The cathepsin D rs17571 polymorphism: Effects on CSF tau concentrations in Alzheimer disease. Hum Mutat 27, 532-537.
67. Palumbo B, Siepi D, Sabalich I, Tranfaglia C, Parnetti L (2008) Cerebrospinal fluid neuron-specific enolase: A further marker of Alzheimer's disease Funct Neurol 23, 93-96.
68. Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I (2008) Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis 14, 17-25.
69. Shih YH, Tsai KJ, Lee CW, Shiesh SC, Chen WT, Pai MC, Kuo YM (2014) Apolipoprotein C-III is an amyloid-betabinding protein and an early marker for Alzheimer's disease. J Alzheimers Dis 41, 855-865.
70. Kovacs DM (2000) alpha2-macroglobulin in late-onset Alzheimer's disease. Exp Gerontol 35, 473-479.
71. Nilselid AM, Davidsson P, Nagga K, Andreasen N, Fredman P, Blennow K (2006) Clusterin in cerebrospinal fluid: Analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int 48, 718-728.
72. Mrak RE, Griffin WS (2005) Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis 8, 369-375.
73. Blennow K (2005) CSF biomarkers for Alzheimer's disease: Use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 5, 661-672.
74. Blennow K, Hampel H,Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.